Research Alert: Edwards Lifesciences: Tavr Sales Expansion Drives Q1 Eps Beat

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Edwards Lifesciences reported strong Q1 results with sales growing 16.7% Y/Y to $1.65B and adjusted EPS of $0.78, beating consensus estimates by $0.05. Operating margin expanded to 31.4% from 29.1% in the prior-year quarter, supported by $500M in quarterly share repurchases. The company benefits from momentum generated by EARLY TAVR study data driving earlier disease intervention, while Boston Scientific's European market exit strengthened EW's TAVR positioning, in our view. EW raised full-year 2026 guidance to 10% constant currency sales growth and $3.00 adjusted EPS midpoint, representing 17% growth vs. 2025. TAVR sales of $1.20B grew 14.4% Y/Y supported by SAPIEN growth globally, with raised guidance to 8% midpoint from 7% previously. TMTT sales surged 51.9% Y/Y driven by PASCAL adoption and higher EVOQUE utilization as procedure volumes rose in the double digits. We expect continued operating margin expansion toward the high end of EW's 28%-29% guidance range in 2026.